| Identification | More | [Name]
Lomerizine hydrochloride | [CAS]
101477-54-7 | [Synonyms]
KB 2796
LOMERIZINE DIHCL
LOMERIZINE DIHYDROCHLORIDE
LOMERIZINE HCL
LOMERIZINE HYDROCHLORIDE
TERRANAS
1-(2,3,4-trimethoxybenzyl)-4-(bis(4-fluorophenyl)methyl)piperazinedihydrochl
1-(bis(4-fluorophenyl)methyl)-4-((2,3,4-trimethoxyphenyl)methyl)-piperazin
1-(bis(4-fluorophenyl)methyl)-4-((2,3,4-trimethoxyphenyl)methyl)piperazined
Lomeizine HCL
KB-2796, Terranas
LOMERIZINEHYDROCHLORTDE
1-[Bis(4-fluorophenyl)methyl]-4-[(2,3,4-trimethoxyphenyl)methyl]piperazine dihydrochloride
1-(4,4'-Difluorobenzhydryl)-4-(2,3,4-trimethoxybenzyl)piperazine·dihydrochloride
Flometizine hydrochloride | [Molecular Formula]
C27H32Cl2F2N2O3 | [MDL Number]
MFCD01703867 | [Molecular Weight]
541.46 | [MOL File]
101477-54-7.mol |
| Chemical Properties | Back Directory | [Appearance]
Colourless Crystalline Solid | [Melting point ]
214-218°C dec. | [storage temp. ]
Inert atmosphere,2-8°C | [solubility ]
DMSO: ≥30mg/mL | [form ]
powder | [color ]
white to tan | [Usage]
A diphenylpiperazine calcium channel blocker. A selective cerebral vasodilator | [Merck ]
14,5563 | [Stability:]
Stable for 1 year from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20°C for up to 1 month. | [CAS DataBase Reference]
101477-54-7(CAS DataBase Reference) |
| Safety Data | Back Directory | [Hazard Codes ]
Xn,N | [Risk Statements ]
22-50 | [Safety Statements ]
61 | [RIDADR ]
UN 3077 9 / PGIII | [WGK Germany ]
3 | [RTECS ]
TK9189000 | [HS Code ]
29335990 | [Toxicity]
LD50 orally in mice: 300 mg/kg (Ohtaka) |
| Hazard Information | Back Directory | [Description]
Lomerizine hydrochloride was introduced as Teranas and Migsis in
Japan for the treatment of migraine. It is the first in its class of dual sodium and
calcium channel blockers to be marketed for this indication. It can be
synthetically obtained by reductive amination of 2,3,4-trimethoxybenzaldehyde
with the appropiate benzhydryl piperazine. In dogs, Lomerizine exerts a potent,
selective and long-lasting vasodilation of cerebral arteries related to a
combination of mechanisms, especially a functional block of L-type voltagesensitive
calcium channels (L-VSCCs). Lomerizine increases cerebral blood flow
compared to peripheral blood flow with only weak effects on systemic arterial
blood pressure. Other mechanisms involved could be blockade of other VSCC
and sodium channels, 5-HT2 and alpha-1 receptors. As a reducing agent of
cortical spreading depression and neurogenic inflammation, Lomerizine was
shown to be useful in migraine. In an open clinical study, it demonstrated
efficacy in the treatment of cluster headache. Moreover, it may have utility in
other neurological diseases such as cerebrovascular ischemia or cerebral
infarction. | [Chemical Properties]
Colourless Crystalline Solid | [Originator]
Akzo Nobel (Netherlands) | [Uses]
A diphenylpiperazine calcium channel blocker. A selective cerebral vasodilator. Antimigraine. | [Brand name]
Teranas;Migsis | [References]
1) Ishii?et al. (2009), Inhibitory effect of lomerizine, a prophylactic drug for migraines, on serotonin-induced contraction of the basilar artery; ?J. Pharmacol. Sci. 111 221
2)?Hara et al. (2004), Clinical potential of lomerizine, a Ca2+ channel blocker as an anti-glaucoma drug: effects on ocular circulation and retinal neuronal damage; Cardiovasc.Drug Rev. 22 199
3)?Ishii et al. (2011), Neuroprotection by lomerizine, a prophylactic drug for migraine, against hydrogen peroxide-induced hippocampal neurotoxicity; Mol. Cell Biochem. 358 1
4) Savigni?et al. (2013), Three Ca2+ channel inhibitors in combination limit chronic secondary degeneration following neurotrauma; ?Neuropharmacology 75 380
5) Tran?et al. (2014), The voltage-gated calcium channel blocker lomerizine is neuroprotective in motor neurons expressing mutant SOD, but not TDP-43; ?J. Neurochem. 130 455
6) O’Hare?et al. (2016), Specific combinations of ion channel inhibitors reduce excessive Ca2+ influx as a consequence of oxidative stress and increase neuronal and glial cell viability in vitro; ?Neuroscience 339 450 |
|
|